TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06690476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose escalation(IPM514 monotherapy)
Description: Drug：IPM514 Intramuscular Injection A total of 7 administrations, including 2 cycles of vaccination with each cycle at QW × 3 doses; there is a 2-weeks interval between the two cycles, then followed by a boost dose 3 weeks after the 2'nd cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose expansion (IPM514 combined with tislelizumab)
Description: Drug：IPM514 Intramuscular Injection Drug：tislelizumab intravenous administration The usage and dosage of the tislelizumab will be based on the drug instructions. IPM514 administration is planned to be concomitant with PD-1 antibody and to be stopped after 9 doses of treatment, while the PD-1 antibody will be continuously administered for a maximum of 1 year.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy cohort(IPM514 combined with tislelizumab, cisplatin and paclitaxel)
Description: Drug：IPM514 Intramuscular Injection Drug：tislelizumab intravenous administration Drug：cisplatin intravenous administration Drug：paclitaxel intravenous administration In this stage, subjects will receive the treatment of IPM514 combined with Tislelizumab, cisplatin and paclitaxel. All four drugs will be administered once every 3 weeks (± 1 day). IPM514 will be administered for the first time on D0, and Tislelizumab, cisplatin and paclitaxel will be administered for the first time on D3 (the administration order: Tislelizumab - paclitaxel - cisplatin). IPM514 will be administered a total of 3 times, and PD-1 antibody, cisplatin and paclitaxel will all be administered a total of 2 times (that is, IPM514 is administered on D0/D21/D42, and Tislelizumab, paclitaxel and cisplatin are administered on D3/D24).
Study: NCT06687499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth-based susceptibility-guided treatment
Description: The investigators design four regimes for H. pylori eradication and participants receive one of the regimens based on susceptibility test. The four regimens are PBAT for those with both amoxicillin and tetracycline susceptible H. pylori; PBAM for those with amoxicillin susceptible but tetracycline resistant H. pylori; PBMT for those with amoxicillin resistant but tetracycline susceptible H. pylori; PBMR for those with both amoxicillin and tetracycline resistant H. pylori. A is amoxicillin (1000 mg thrice daily), B is colloidal bismuth subcitrate (120 mg thrice daily), M is metronidazole (500 mg thrice daily), P is a proton pump inhibitor, i.e., esomeprazole (40 mg twice daily), R is rifabutin (150 mg twice daily), and T is tetracycline (500 mg thrice daily). The treatment duration is 14 days for all regimens.
Study: NCT06691737

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration
Description: Whole body vibration consists of 3-minute vibrations with a 30-second break. Participants were asked to step onto the platform barefoot and position their feet 3 from the center of the platform, with feet pointing forward, knees slightly bent, and upper limbs along the body. The training was divided into two parts: week 1 with a frequency of 20 Hz, and a constant amplitude of 3 mm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration
Description: Whole body vibration consists of 3-minute vibrations with a 30-second break. Participants were asked to step onto the platform barefoot and position their feet 3 from the center of the platform, with feet pointing forward, knees slightly bent, and upper limbs along the body. The training was divided into two parts: week 1 with a frequency of 20 Hz, and a constant amplitude of 3 mm.
Study: NCT06690970

Intervention type: DIAGNOSTIC_TEST
Intervention: 68Ga/18F-PSMA
Description: Each subject receive a single intravenous injection of 68Ga/18F-PSMA, and undergo PET/CT imaging within the specificed time.
Study: NCT06687993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil 2.5 mg
Description: 2.5 mg daily oral intake for 90 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg
Description: 5 mg daily oral intake for 90 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: daily oral intake for 90 days
Study: NCT06687577

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DBT-C
Description: Tobacco cessation treatment adapted for high risk population.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Standard behavioral tobacco cessation treatment.
Study: NCT06634160

Intervention type: DIAGNOSTIC_TEST
Intervention: Fibroscan
Description: Evaluation of the prevalence of steatosis by measuring ultrasound attenuation with Fibroscan® (non-invasive method, at a distance from a meal (3h fasting)).

Intervention type: OTHER
Intervention: Sample collection
Description: 20 mL whole blood sample
Study: NCT05721755

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT and/or PET/CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT and/or PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study: NCT06429683

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sexually transmitted diseases training for young adolescents aged 17-21
Description: Education
Study: NCT05979090

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mastery learning in communication skills
Description: Participants will undergo simulation-based mastery learning curriculum in difficult conversations.
Study: NCT06211504

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProStop, sinus tarsi implant (STI)
Description: Insertion of a sinus tarsi implant (ProStop from Arthrex) in sinus tarsi

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional surgery
Description: MDCO - medial displacement calcaneal osteotomy FDL transfer - flexor digitorum longus tendon transfer to the navicular bone Spring ligament repair - reconstruction of the spring ligament Strayer's procedure - gastrocnemius recession (if necessary) Cotton osteotomy - medial cuneiform opening wedge osteotomy (if necessary)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional surgery
Description: MDCO - medial displacement calcaneal osteotomy FDL transfer - flexor digitorum longus tendon transfer to the navicular bone Spring ligament repair - reconstruction of the spring ligament Strayer's procedure - gastrocnemius recession (if necessary) Cotton osteotomy - medial cuneiform opening wedge osteotomy (if necessary)
Study: NCT05853458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: Hydroxyurea is commercially available in Germany and will be prescribed based on clinical judgment
Study: NCT05635084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YN001
Description: Dose ranges from 2-90mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for YN001
Description: 5% dextrose injection to mimic the YN001
Study: NCT06503653

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: syncope channel
Description: The procedures and investigations proposed for the etiological diagnosis of low-risk or neither high nor low syncope and included in the study are those recommended by the European Society of Cardiology.~No additional procedures, invasive or non-invasive explorations or blood sampling not provided for as part of routine care will be offered or carried out as part of the study.~The only change in practice for patients included in the syncope pathway The only change in practice concerns the grouping of patients included in the syncope pathway into a single day at a day hospital within 10 days of their emergency consultation.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: routine care
Description: The procedures and investigations proposed for the etiological diagnosis of low-risk or neither high nor low syncope and included in the study are those recommended by the European Society of Cardiology.in routine care, medical examinations are carried out by specialists such as cardiologists who do not practice in hospitals
Study: NCT06324487

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Exercises
Description: Electrotherapy, stretching of the capsules, strengthening, ROM exercises, proprioceptive exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Exercises
Description: Electrotherapy, stretching of the capsules, strengthening, ROM exercises, proprioceptive exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction Therapy
Description: Strengthening exercises performed by using cuff surrounding proximal part of the arm.
Study: NCT05848011

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: lorigerlimab
Description: Lorigerlimab is a DART® molecule that binds PD-1 and CTLA-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Docetaxel Injection is a cytotoxic anticancer drug approved to treat prostate cancer

Intervention type: DRUG
Group type: OTHER
Intervention: docetaxel
Description: Docetaxel Injection is a cytotoxic anticancer drug approved to treat prostate cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: A corticosteroid drug approved for use with docetaxel in the treatment of prostate cancer

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisone
Description: A corticosteroid drug approved for use with docetaxel in the treatment of prostate cancer
Study: NCT05674747

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Swift Microwave treatment - weekly x 4wks
Description: Swift device set up to 7-9 Watts applied locally for up to a 3 second burst to the toenail.~Start at 9 Watts and apply locally for up to a 3 second burst; adjust the dose and duration as is tolerable for the subject. Repeat on the infected parts of the nail as is tolerable for the subjects ( up to 5 repetitions).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Swift Microwave treatment - Every other week x 4wks
Description: Swift device set up to 7-9 Watts applied locally for up to a 3 second burst to the toenail.~Start at 9 Watts and apply locally for up to a 3 second burst; adjust the dose and duration as is tolerable for the subject. Repeat on the infected parts of the nail as is tolerable for the subjects ( up to 5 repetitions).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Swift Microwave treatment - Every other week x 24wks
Description: Swift device set up to 7-9 Watts applied locally for up to a 3 second burst to the toenail.~Start at 9 Watts and apply locally for up to a 3 second burst; adjust the dose and duration as is tolerable for the subject. Repeat on the infected parts of the nail as is tolerable for the subjects ( up to 5 repetitions).
Study: NCT04935879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inclacumab
Description: Inclacumab will be supplied in single use 10 mL vials at a concentration of 50 mg/mL. One vial contains 500 mg of inclacumab. This is a liquid concentrate for IV infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be supplied in single use 10 mL vials containing the same ingredients without the active drug. Placebo will be prepared as a liquid concentrate for IV infusion and administered in the same manner as active study drug
Study: NCT06513364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WH002
Description: Group A（ddWH002-ddEC）： Regimen for Group A during Cycles 1-Cycles 4:WH002， 260 mg/m² administered intravenously on Day 1, with a cycle length of 2 weeks (Q2W), repeated for a total of 4 cycles.~Regimen for Group A during Cycles 5-Cycles 8:~• Epirubicin Hydrochloride 90 mg/m² and Cyclophosphamide for Injection 600 mg/m², both administered intravenously on Day 1, with each cycle lasting 2 weeks (Q2W), continued for 4 consecutive cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel injection
Description: Group B (ddP-ddEC):~Regimen for Group B during Cycles C1-C4:~• Paclitaxel Injection (Paclitaxel®) 175 mg/m², administered intravenously on Day 1, with a cycle duration of 2 weeks (Q2W), repeated for a total of 4 cycles.~Regimen for Group B during Cycles C5-C8:~• Epirubicin Hydrochloride 90 mg/m² and Cyclophosphamide for Injection 600 mg/m², both administered intravenously on Day 1, with cycles recurring every 2 weeks (Q2W), for a series of 4 cycles.
Study: NCT05413473

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR guided radiotherapy
Description: MR guided radiotherapy using the Alberta linac-MR P3 system
Study: NCT04706182

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF)
Description: Platelet rich fibrin (PRF) serves as a structural reservoir of cytokines such as platelet-derived growth factor (PDGF), transforming growth factor (TGF-b), insulin-like growth factor (IGF), platelet factor 4 (PF4) and vascular endothelial growth factor (VEGF) which aids in healing and preventing infection. PRF will be prepared as recommended by the manufacturer (Intra-Lock International) by centrifuging 20 mL of the subject's venous blood for 12 minutes at 2700 rpm, followed by compression. The fibrin clot will then be applied to the SSO site prior to fixation. The blood draw for the PRF will be performed approximately 15 minutes prior to fixation of the mandible. 20 mL will be drawn for each PRF side treated. The blood venous draw will be from the subject's arm or from an existing intra-venous line.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF)
Description: Platelet rich fibrin (PRF) serves as a structural reservoir of cytokines such as platelet-derived growth factor (PDGF), transforming growth factor (TGF-b), insulin-like growth factor (IGF), platelet factor 4 (PF4) and vascular endothelial growth factor (VEGF) which aids in healing and preventing infection. PRF will be prepared as recommended by the manufacturer (Intra-Lock International) by centrifuging 20 mL of the subject's venous blood for 12 minutes at 2700 rpm, followed by compression. The fibrin clot will then be applied to the SSO site prior to fixation. The blood draw for the PRF will be performed approximately 15 minutes prior to fixation of the mandible. 20 mL will be drawn for each PRF side treated. The blood venous draw will be from the subject's arm or from an existing intra-venous line.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Proximal segment grooving (PSG)
Description: Proximal segment grooving is a mechanical method to create additional space within the inferior alveolar canal to allow the IAN to rest without compression or trauma. The surgeon uses a round or acrylic bur to cautiously remove any bony spicules, and remove cancellous bone in the proximal mandibular segment. PSG will be done by using an acrylic round bur on a surgical handpiece to remove 3 to 4 mm of cancellous bone where the IAN will passively rest into prior to fixation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Proximal segment grooving (PSG)
Description: Proximal segment grooving is a mechanical method to create additional space within the inferior alveolar canal to allow the IAN to rest without compression or trauma. The surgeon uses a round or acrylic bur to cautiously remove any bony spicules, and remove cancellous bone in the proximal mandibular segment. PSG will be done by using an acrylic round bur on a surgical handpiece to remove 3 to 4 mm of cancellous bone where the IAN will passively rest into prior to fixation.
Study: NCT04962321

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Education
Description: Psychoeducation on relationships between mood, anxiety, eating, and exercise behaviors. One one-hour session each week for 8 weeks.
Study: NCT04933279

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: iodine-containg spareribs soup
Description: administrated a 150 ml - 200 ml of iodine-containg spareribs soup delivering ≈ 600 µg or 1200 µg iodine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: intrinsic iodine in natural kelp
Description: administrated 45 g or 80 g natural kelp delivering ≈ 600 µg or 1200 µg iodine (intrinsic iodine). The natural kelp will be approximately produced in an experimental barn feeding supplementary iodine to reach a final iodine intake of ≈ 600 µg or 1200 µg. The iodine intake of natural kelp will be adjusted to the required dose by determing iodine content in the natural kelp.
Study: NCT06695702

Intervention type: OTHER
Intervention: the effect of work-based learning on the level of knowledge
Description: The benefit of workbased learning on nursing students' knowledge of oncology symptom management
Study: NCT06687304

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Light enhancement
Description: Light recipe that mimics the varying daylight of the day
Study: NCT06686706

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IASTM
Description: Graston therapy-8 min per session~Procedure:~The patient will be lying down with their knee bent 30 degrees. After a 5-minute ultrasound treatment and static stretching exercises.Treatment will be administered using the Graston tool (using the sweep approach). Applying a moderate amount of effort from the medial side of the heel to the metatarsals and from the metatarsals to the medial side of the heel, to-and-fro stroking at a 60° angle will be done on the sole of the foot for approximately eight minutes (60-70 strokes per minute with a 5- to 10-second rest interval. A cold pack will be used for five minutes after therapy. The GT session will last approximately 30 minutes.~Conventional Therapy:~Therapeutic ultrasound for 5 min Stretching of plantar fascia 5 reps with 10 sec hold) Cold therapy for 5 min Functional status and Quality of Life (QOL) will be assessed before and after treatment of 4 weeks using using tools.~Intervention will be conducted once a week for 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KT group
Description: Kinesio tapping (left there for 3 days)~Procedure:~We will use a standard 2 (5 cm) kinesiology tape. Fascia tape will be applied to the plantar fascia, and it will be left there for three days. For four weeks, it will be applied once a week. The patient will be in a prone position, lying with the ankle joints in a neutral position while applying tape. With the toes extended against the bed or ground. The tape will be marked on the Achilles tendon. It will be cut longitudinally into five slices of equal width. It will be applied to the forefoot by stretching it by 25%. The last strap will be applied with gentle compression across the bases of the five slices beneath the foot and wrapped around the rear foot.(5) Conventional Therapy Therapeutic ultrasound for 5 min Stretching of plantar fascia 5 reps with 10 sec hold) Cold therapy for 5 min
Study: NCT06687122

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 3 whole eggs
Description: Participants will be free-living and will not be supplied with any other food except for the eggs during the intervention period with no restrictions of energy intake.
Study: NCT06686563

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Group: Gamma stimulation
Description: Participants in this group be stimulated with gamma frequency (39-42 Hz). The frequency of the intervention will be 5 times a week, with the AVNS being used twice a week for 20 minutes (a minimum of 20 sessions - 8 to 12 weeks) and the other 3 days being spent at home with 20 minutes of audio frequency stimulation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group: Theta stimulation
Description: Participants in this group will be stimulated with theta frequency (4-7 Hz). The frequency of the intervention will be 5 times a week, with the AVNS being used twice a week for 20 minutes (a minimum of 20 sessions - 8 to 12 weeks) and the other 3 days being spent at home with 20 minutes of audio frequency stimulation.
Study: NCT06442397

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anti-Inflammatory Lifestyle Intervention
Description: Content includes training in empirically-supported strategies to improve psychological function (e.g., restructuring negative thoughts, distress tolerance), with a focus on changing discrete behaviors linked to inflammation (e.g., sleep, processed foods, physical activity), all intertwined with evidence-based behavior change content adapted to meet the needs of EACS. Participants will also receive digital tools to facilitate daily self-monitoring (Fitbit activity monitor, wireless scales, self-monitoring app) and generate information for tailored weekly e-coaching
Study: NCT04917939

Intervention type: OTHER
Intervention: RNA sequencing
Description: Samples in both groups will be sequenced by single-cell sequencing and spatial transcription sequencing.

Intervention type: OTHER
Intervention: RNA sequencing
Description: Samples in both groups will be sequenced by single-cell sequencing and spatial transcription sequencing.